Version 2 2024-06-12, 15:38Version 2 2024-06-12, 15:38
Version 1 2021-10-20, 16:27Version 1 2021-10-20, 16:27
journal contribution
posted on 2024-06-12, 15:38authored byDL Bhatt, K Fox, RA Harrington, LA Leiter, SR Mehta, T Simon, M Andersson, A Himmelmann, W Ridderstråle, C Held, PG Steg, R Diaz, J Amerena, K Huber, P Sinnaeve, JC Nicolau, JFK Saraiva, I Petrov, R Corbalán, J Ge, Q Zhao, R Botero, P Widimský, SD Kristensen, J Hartikainen, N Danchin, H Darius, TH Fat, RG Kiss, P Pais, E Lev, LD Luca, S Goto, GAR López, JH Cornel, F Kontny, F Medina, N Babilonia, G Opolski, D Vinereanu, D Zateyshchikov, M Ruda, O Elamin, F KováŘ, AJ Dalby, MH Jeong, H Bueno, S James, CE Chiang, D Tresukosol, Z Ongen, K Ray, A Parkhomenko, D McGuire, M Kosiborod, TQ Nguyen
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study